Business UpdateApr 29, 2026, 11:02 AM
PatentVest Pulse: Weight Loss Drug IP Race Beyond 28.7% Loss
AI Summary
PatentVest released its latest "PatentVest Pulse" report, titled "The Last 20%: Retatrutide, the Glucagon Paradox, and the Race to Own Surgery-Level Weight Loss Without Surgery." The report analyzes the intellectual property landscape of weight loss drugs, highlighting Eli Lilly's retatrutide achieving 28.7% mean weight loss. It emphasizes that the focus is shifting from drug development to controlling the IP, mapping the full pipeline, deal layers, and IP structures that will define value capture in this competitive market.
Key Highlights
- PatentVest released its "PatentVest Pulse" report on weight loss drug IP.
- Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric outcomes.
- The report highlights a shift from drug development to controlling IP in the sector.
- Key players include Novo Nordisk, Pfizer, Hanmi, Innovent, Hengrui, and Sanofi.
- Sanofi holds the largest IP position with 27 programs without a disclosed asset.
- The report maps the full pipeline, deal layer, and IP structure defining value capture.
Price Impact
More from MDBH